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APC = antigen presenting cell; CTL = cytotoxic T-lymphocyte; DC = dendritic cell; IFN-γ = interferon-γ; IL = interleukin; IL-1ra = IL-1 receptor
antagonist; MHC = major histocompatibility complex; Th = T helper cell; TLR = Toll-like receptor; TNF = tumor necrosis factor
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What is the third signal?
Dendritic cells (DCs) are the professional antigen-present-
ing cells (APCs) of the body, and as such play a key role
in the signaling of T cells for effector responses to antigen.
Various co-stimulatory and adhesive interactions between
DCs and T cells are able to drive proliferative, proinflam-
matory cytokine and cytotoxic effector functions of T cells
[1]. The effector response made to antigen presented by
DCs depends on the co-stimulatory signals delivered to
T cells along with the antigen signal presented in the
context of MHC molecules [2]. Lafferty’s concept of a
second or co-stimulatory signal stands as a key model for
our understanding of the generation of immunity, and also for
our understanding of the basis for peripheral tolerance [3].
In recent years, through the study of interactions taking
place at the immunological synapse, at which T cells are
signaled by antigen-bearing APCs, several groups have
studied the minimal requirements of CD4+ and CD8+
T cells for these effector functions. Mescher et al., for
example, have done so using a simple system of beads
conjugated with MHC and antigen – whose density can
be varied – (signal 1), and various membrane co-stimula-
tory molecules (signal 2), such as CD80/86 or CD54
(ICAM-1). In this context, they have shown for CD8+ T
cells that signals 1 and 2 are sufficient for proliferation and
cytokine production, but that a third signal, IL-12, is
required for cytotoxic effector function [4]. The authors
indicate that IL-12 is not the only soluble factor which can
function as a third signal for CD8+ T cells, but that it can
be substituted by other, as yet unknown, factors.
In a recent paper, Mescher et al. extend the concept of the
third signal in vivo to show that the presence of signals 1
and 2 but the absence of IL-12 results in peripheral toler-
ance in the CD8+ T-cell compartment [5]. Thus, CD8+
T cells are able to proliferate and to produce IFN-γ in vivo
in the absence of IL-12, but this cytokine production and
cytotoxic T-lymphocyte (CTL) activity are limited. The data
are consistent with the work of others, showing the impor-
tant role of IL-12 in driving IFN-γ effector function by T
cells [6]. Further upstream, IL-12 production by DCs has
been shown to be driven by dual TLR (toll-like receptor)
and CD40 signals [7]. In this regard, it is of interest that
the minimum required signals for CD154 (CD40L) expres-
sion by CD4+ T cells are CD80/86 and CD54, even in the
absence of signal 1 [8].
The signal 3 requirements for CD4+ T cells are less well
defined. Indeed it is more difficult to define an effector
function beyond cytokine production for CD4+ T cells that
is equivalent to the “higher order” effector function repre-
sented by CTL activity for CD8+ T cells. This is paradoxical,
because higher order consequences of CD4+ T-cell helper
function for B cells, CTL activity and memory are driven
largely by CD154 as well as other CD40-dependent and
-independent co-stimulatory interactions, including OX40,
41BB, ICOS and other members of the B7 family [1]. Nev-
ertheless, using the readout of IFN-γ production by CD4+ T
cells as a measure of T helper type 1 (Th1) effector func-
tion, Mescher et al. previously suggested that IL-1β could
act as a third signal for CD4+ T cells [9].
Implications for autoimmune disease
pathogenesis
Although most autoimmune diseases are driven principally
by autoreactivity of CD4+ T cells to self-antigen presented
in the context of MHC class II, some – notably type 1
diabetes – show a clear association with CD8+ T-cell
autoreactivity. IL-12 is a major driver in the pathogenesis of
type 1 diabetes in NOD mice, and both IFN-γ and CTL
effector function of CD8+ T cells in response to self-antigen
are critical for disease development and progression [10].
Over the last 10 years, fascinating roles for IL-1β in
autoimmune disease pathogenesis have also emerged. As
a “third signal,” it appears to have profound roles in the ini-
tiation and persistence of autoimmunity beyond its better-
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known roles in tissue inflammation, and damage in innate
immunity. Besides its capacity to drive the production of
IFN-γ and IL-2 by CD4+ T cells directly, IL-1β has been
shown by several groups to act on the DC to enhance the
production of proinflammatory cytokines, including TNFα
and more significantly IL-12, which itself has important
effects on the production of IFN-γ by CD4+ T cells [11].
Kopf et al. recently showed, in a model of autoimmune
myocarditis, that mice deficient in IL-1 receptor-1 were
resistant to disease induction, but that this resistance
could be overcome by the transfer of wild type DCs
pulsed with autoantigen, since IL-1 signaling of the DCs
now induced IL-12 production and effective autoantigen
presentation [12]. Of interest, Sedgwick et al. have
demonstrated that, rather than IL-12, the more recently dis-
covered IL-23, also with the capacity to drive production of
IFN-γ by CD4+ T cells, was essential for the pathogenesis
of the autoimmune central nervous system inflammatory
disease, experimental allergic encephalomyelitis [13].
Lastly, an IL-1 receptor antagonist (IL-1ra) deficiency on a
BALB/c but not C57Bl/6 background leads to the sponta-
neous development of inflammatory arthritis [14-16]. This
highlights the critical role of IL-1ra in the constitutive main-
tenance of peripheral tolerance, and in counterbalancing
the proinflammatory effects of IL-1 and IL-17.
Conclusions
Although apparently simple, the concept of a third
(cytokine) signal for T-cell responses to antigen is also
powerful, in that elucidation of third signals in simple in
vitro systems has enabled essential ingredients that drive
spontaneous autoimmunity to be defined. A model for
T-cell activation can be envisaged in which each T cell
integrates a range of proinflammatory, stimulatory and
regulatory signals to determine the effector functions
activated. In this model, one can imagine that in auto-
immune-prone individuals, the contributions of each signal
may be altered, through polymorphisms in the genes
responsible for production of, or response to, the signal.
Alternatively, environmental factors, such as infectious or
toxic signals, may reset the signal threshold. Together, the
genetically determined settings of the T-cell response
mechanism and the environmental exposure history, for
each individual, govern the risk of autoimmune disease
manifestation. Finally, the mandatory contribution of
signals other than antigen to T-cell activation supports the
current model in which interaction of the innate and adap-
tive immune systems determines the outcome of antigen
exposure not only at sites of tissue inflammation and
destruction, but also at the time of antigen presentation.
This model highlights the role of innate and adaptive
immune system interactions in the failure of peripheral tol-
erance. It will be fascinating in the future to extend this
concept to understand the impact of third signals on
failure of mechanisms of central tolerance in the thymus.
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